Center for Hemobiology-Blood Transfusion, Mustapha University Hospital, Faculty of Medicine of Algiers, Algiers, Algeria.
Laboratory of molecular biology and UVSQ, UMR 1179, Ambroise Paré Hospital, Boulogne-Billancourt, France.
Haemophilia. 2022 Sep;28(5):822-831. doi: 10.1111/hae.14579. Epub 2022 Apr 30.
The incidence of afibrinogenemia had not been previously reported in Algeria. Afibrinogenemia patients are prone to both haemorrhagic and thrombotic complications. Predictive markers of thrombosis in afibrinogenemia patients are not existent.
Clinical and biological data from 46 afibrinogenemia patients are reported. Biological investigations included routine tests, genetics analysis and thrombin generation.
FGA mutations (four novel and four previously described) and FGB mutations (seven mutations; five novels) were homozygous in all but one family as a result of 28 consanguineous marriages out of 30 discrete families. Incidence of afibrinogenemia in Algeria is at least 3 per million births. Umbilical bleeding was reported in 39/46 cases and was the main discovery circumstance. We also report post trauma or post-surgery (3/46) bleeding and spontaneous deep vein thrombosis (DVT) in adulthood (1/46), as discovery circumstances. The median age (10.5-year-old) of the population reported here explains why there are few hemarthrosis and obstetrical or gynaecological complications in this series. Thrombotic events were reported in seven patients (four spontaneous). Endogenous Thrombin Potential was significantly increased in thrombosis-prone patients compared to afibrinogenemic patients with and without personal or familial history (1118 vs. 744 and 817 nM IIa × min, respectively).
The incidence of afibrinogenemia in Algeria is the consequence of consanguineous marriage in families carrying private mutations. The thrombin generation test (TGT) could identify, among afibrinogenemic patients, those presenting a thrombotic risk.
在阿尔及利亚,以前没有报道过无纤维蛋白原血症的发病率。无纤维蛋白原血症患者容易发生出血和血栓并发症。无纤维蛋白原血症患者的血栓形成预测标志物尚不存在。
报告了 46 例无纤维蛋白原血症患者的临床和生物学数据。生物学研究包括常规检查、基因分析和凝血酶生成。
所有 30 个离散家庭中有 28 个家庭存在近亲结婚,导致 46 个家系中所有患者均为 FGA 突变(4 个新突变和 4 个先前描述的突变)和 FGB 突变(7 个突变;5 个新突变)纯合子。阿尔及利亚无纤维蛋白原血症的发病率至少为每百万出生 3 例。46 例中有 39 例报告脐出血,这是主要的发现情况。我们还报告了创伤后或手术后(46 例中的 3 例)出血和成年期自发性深静脉血栓形成(46 例中的 1 例),这是发现的情况。报告的人群的中位年龄(10.5 岁)解释了为什么在这个系列中很少有膝关节血肿和产科或妇科并发症。有 7 例患者(4 例自发性)报告有血栓事件。与有个人或家族史的无纤维蛋白原血症患者(分别为 744 和 817 nM IIa×min)相比,血栓形成倾向患者的内源性凝血酶潜能显著升高(1118 nM IIa×min)。
阿尔及利亚无纤维蛋白原血症的发病率是家庭中携带私人突变的近亲结婚的结果。凝血酶生成试验(TGT)可以在无纤维蛋白原血症患者中识别出有血栓形成风险的患者。